Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Abstract 311: Optimization of treatment schedule for the combination therapy of ATR inhibitor elimusertib and PARP inhibitor niraparib in preclinical tumor models

Antje Margret Wengner, Gerhard Siemeister, Bart Ploeger, Lisa Ehresmann, Nils Guthof, Gary Wilkinson

Cancer Res (2023) 83 (7_Supplement): 311.

https://doi.org/10.1158/1538-7445.AM2023-311

Published: 04 April 2023

View articletitled, Abstract 311: Optimization of treatment schedule for the combination therapy of ATR inhibitor elimusertib and PARP inhibitor niraparib in preclinical tumor models

Journal Articles

Abstract 2077: Activity of DHODH inhibitor BAY2402234 in subcutaneous and intracranial models of SCLC

Stefan Kaulfuss, Andreas Janzer, Gerhard Siemeister, Renan Borowicz, Katrin Jaensch, Katrin Gutberlet, Ricarda Schlenz, Andrea Triller, Ashley Eheim, Michael Jeffers, Sven Christian

Cancer Res (2021) 81 (13_Supplement): 2077.

https://doi.org/10.1158/1538-7445.AM2021-2077

Published: 01 July 2021

View articletitled, Abstract 2077: Activity of DHODH inhibitor BAY2402234 in subcutaneous and intracranial models of SCLC

Journal Articles

Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation

Brian D. Yard, Priyanka Gopal, Kristina Bannik, Gerhard Siemeister, Urs B. Hagemann, Mohamed E. Abazeed

Cancer Res (2019) 79 (21): 5640–5651.

https://doi.org/10.1158/0008-5472.CAN-19-0859

Published: 01 November 2019

View articletitled, Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation

Includes: Supplementary data

Journal Articles

Abstract 3927: Radium-223 α-particle radiation: Characterization of the in vitro effects on cancer cells in monotherapy and in combination with DNA repair inhibitors

Kristina Bannik, Sabine Zitzmann-Kolbe, Arne Scholz, Sabrina Jarke, Marco Jarzombek, Andreas Sutter, Gerhard Siemeister, Dominik Mumberg

Cancer Res (2019) 79 (13_Supplement): 3927.

https://doi.org/10.1158/1538-7445.AM2019-3927

Published: 01 July 2019

View articletitled, Abstract 3927: Radium-223 α-particle radiation: Characterization of the in vitro effects on cancer cells in monotherapy and in combination with DNA repair inhibitors

Journal Articles

Abstract 272: Synergistic activity of the ATR inhibitor BAY1895344 in combination with immune checkpoint inhibitors in preclinical tumor models

Antje Margret Wengner, Dennis Kirchhoff, Lars Roese, Sandra Berndt, Gerhard Siemeister, Bertolt Kreft, Dominik Mumberg

Cancer Res (2019) 79 (13_Supplement): 272.

https://doi.org/10.1158/1538-7445.AM2019-272

Published: 01 July 2019

View articletitled, Abstract 272: Synergistic activity of the ATR inhibitor BAY1895344 in combination with immune checkpoint inhibitors in preclinical tumor models

Journal Articles

Abstract 321: Synergistic activity of the ATR inhibitor BAY 1895344 in combination with DNA damage inducing and DNA repair compromising therapies in preclinical tumor models

Antje Margret Wengner, Gerhard Siemeister, Ulrich Luecking, Julien Lefranc, Kirstin Meyer, Eleni Lagkadinou, Bernard Haendler, Pascale Lejeune, Dominik Mumberg

Cancer Res (2018) 78 (13_Supplement): 321.

https://doi.org/10.1158/1538-7445.AM2018-321

Published: 01 July 2018

View articletitled, Abstract 321: Synergistic activity of the ATR inhibitor BAY 1895344 in combination with DNA damage inducing and DNA repair compromising therapies in preclinical tumor models

Journal Articles

Abstract 849: Synergistic effect of MSLN-TTC in combination with DNA damage response inhibitors

Katrine Wickstroem, Urs B. Hagemann, Antje M. Wengner, Alexander Kristian, Christine Ellingsen, Gerhard Siemeister, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Lars Linden, Bertolt Kreft, Dominik Mumberg, Hanno Wild, Karl Ziegelbauer, Alan Cuthbertson

Cancer Res (2018) 78 (13_Supplement): 849.

https://doi.org/10.1158/1538-7445.AM2018-849

Published: 01 July 2018

View articletitled, Abstract 849: Synergistic effect of MSLN-TTC in combination with DNA damage response inhibitors

Journal Articles

Abstract 838: Synergistic in vivo activity of the ATR inhibitor BAY 1895344 in combination with the targeted alpha therapy radium-223 dichloride in a preclinical tumor model mimicking bone metastatic castration-resistant prostate cancer (mCRPC)

Antje Margret Wengner, Gerhard Siemeister, Ulrich Luecking, Julien Lefranc, Arne Scholz, Mari Suominen, Kirstin Meyer, Eleni Lagkadinou, Dominik Mumberg

Cancer Res (2018) 78 (13_Supplement): 838.

https://doi.org/10.1158/1538-7445.AM2018-838

Published: 01 July 2018

View articletitled, Abstract 838: Synergistic in vivo activity of the ATR inhibitor BAY 1895344 in combination with the targeted alpha therapy radium-223 dichloride in a preclinical tumor model mimicking bone metastatic castration-resistant prostate cancer (mCRPC)

Journal Articles

Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity

Gerhard Siemeister, Anne Mengel, Wilhelm Bone, Jens Schröder, Sabine Zitzmann-Kolbe, Hans Briem, Amaury E. Fernández-Montalván, Simon Holton, Ursula Mönning, Oliver von Ahsen, Sandra Johanssen, Arwed Cleve, Marion Hitchcock, Kirstin Meyer, Franz von Nussbaum, Michael Brands, Dominik Mumberg, Karl Ziegelbauer

Cancer Res (2017) 77 (13_Supplement): 287.

https://doi.org/10.1158/1538-7445.AM2017-287

Published: 01 July 2017

View articletitled, Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity

Journal Articles

Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models

Ulrich T. Luecking, Julien Lefranc, Antje Wengner, Lars Wortmann, Hans Schick, Hans Briem, Gerhard Siemeister, Philip Lienau, Christoph Schatz, Benjamin Bader, Gesa Deeg, Franz von Nussbaum, Michael Brands, Dominik Mumberg, Karl Ziegelbauer

Cancer Res (2017) 77 (13_Supplement): 983.

https://doi.org/10.1158/1538-7445.AM2017-983

Published: 01 July 2017

View articletitled, Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models

Journal Articles

Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models

Antje Margret Wengner, Gerhard Siemeister, Ulrich Luecking, Julien Lefranc, Philip Lienau, Gesa Deeg, Eleni Lagkadinou, Li Liu, Sven Golfier, Christoph Schatz, Arne Scholz, Franz von Nussbaum, Michael Brands, Dominik Mumberg, Karl Ziegelbauer

Cancer Res (2017) 77 (13_Supplement): 836.

https://doi.org/10.1158/1538-7445.AM2017-836

Published: 01 July 2017

View articletitled, Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models

Journal Articles

Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops

Ulrich T. Luecking, Arne Scholz, Dirk Kosemund, Rolf Bohlmann, Hans Briem, Philip Lienau, Gerhard Siemeister, Ildiko Terebesi, Kirstin Meyer, Katja Prelle, Ray Valencia, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Karl Ziegelbauer, Michael Brands

Cancer Res (2017) 77 (13_Supplement): 984.

https://doi.org/10.1158/1538-7445.AM2017-984

Published: 01 July 2017

View articletitled, Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops

Journal Articles

Abstract 2718: Synthesis and characterization of novel benzylpyrazole-based BUB1 kinase inhibitors with anti-tumor activity

Marion Hitchcock, Gerhard Siemeister, Hans Briem, Amaury Ernest Fernandez-Montalvan, Simon Holton, Anne Mengel, Ursula Mönning, Michael Brands, Karl Ziegelbauer, Dominik Mumberg, Franz von Nussbaum.

Cancer Res (2016) 76 (14_Supplement): 2718.

https://doi.org/10.1158/1538-7445.AM2016-2718

Published: 15 July 2016

View articletitled, Abstract 2718: Synthesis and characterization of novel benzylpyrazole-based BUB1 kinase inhibitors with anti-tumor activity

Journal Articles

Abstract 2725: Probing mitotic functions of BUB1 kinase using the small molecule inhibitors BAY-320 and BAY-524

Anna P. Baron, Conrad von Schubert, Fabien Cubizolles, Gerhard Siemeister, Marion Hitchcock, Anne Mengel, Jens Schröder, Amaury Fernández-Montalván, Martin Lange, Franz von Nussbaum, Dominik Mumberg, Erich Nigg

Cancer Res (2016) 76 (14_Supplement): 2725.

https://doi.org/10.1158/1538-7445.AM2016-2725

Published: 15 July 2016

View articletitled, Abstract 2725: Probing mitotic functions of BUB1 kinase using the small molecule inhibitors BAY-320 and BAY-524

Journal Articles

Abstract DDT02-02: BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis

Arne Scholz, Ulrich Luecking, Gerhard Siemeister, Philip Lienau, Ulf Boemer, Peter Ellinghaus, Annette O. Walter, Ray Valencia, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Michael Brands, Karl Ziegelbauer

Cancer Res (2015) 75 (15_Supplement): DDT02-02.

https://doi.org/10.1158/1538-7445.AM2015-DDT02-02

Published: 01 August 2015

View articletitled, Abstract DDT02-02: BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis

Journal Articles

Abstract 2828: Rapid identification of potent and highly selective, oral PTEFb Inhibitor BAY 1143572 with first in class potential

Cancer Res (2015) 75 (15_Supplement): 2828.

https://doi.org/10.1158/1538-7445.AM2015-2828

Published: 01 August 2015

View articletitled, Abstract 2828: Rapid identification of potent and highly selective, oral PTEFb Inhibitor BAY 1143572 with first in class potential

Journal Articles

Abstract 3098: The effects of a pan-cyclin dependent kinase (CDK) inhibitor and its combination with cisplatin in nasopharyngeal carcinoma (NPC)

Pei Li Lim, John SW Low, Gerhard Siemeister, Boon Cher Goh, Wen-son Hsieh

Cancer Res (2015) 75 (15_Supplement): 3098.

https://doi.org/10.1158/1538-7445.AM2015-3098

Published: 01 August 2015

View articletitled, Abstract 3098: The effects of a pan-cyclin dependent kinase (CDK) inhibitor and its combination with cisplatin in nasopharyngeal carcinoma (NPC)

Journal Articles

Abstract 3090: Novel Mps1 kinase inhibitors with potent anti-tumor activity

Cancer Res (2015) 75 (15_Supplement): 3090.

https://doi.org/10.1158/1538-7445.AM2015-3090

Published: 01 August 2015

View articletitled, Abstract 3090: Novel Mps1 kinase inhibitors with potent anti-tumor activity

Journal Articles

Abstract 4540: SAC abrogation by MPS1 kinase inhibition: preclinical proof of concept of a novel approach to tumor treatment

Dominik Mumberg, Gerhard Siemeister, Antje M. Wengner, Marcus Koppitz, Volker Schulze, Benjamin Bader, Stefan Prechtl, Bertolt Kreft, Karl Ziegelbauer

Cancer Res (2014) 74 (19_Supplement): 4540.

https://doi.org/10.1158/1538-7445.AM2014-4540

Published: 01 October 2014

View articletitled, Abstract 4540: SAC abrogation by MPS1 kinase inhibition: preclinical proof of concept of a novel approach to tumor treatment

Journal Articles

Abstract 4538: BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity

Arne Scholz, Ulrich Lücking, Gerhard Siemeister, Philip Lienau, Knut Eis, Antje Wengner, Kirstin Petersen, Ulf Bömer, Peter Nussbaumer, Axel Choidas, Gerd Rühter, Jan Eickhoff, Carsten Schultz-Fademrecht, Bert Klebl, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Michael Brands, Karl Ziegelbauer

Cancer Res (2014) 74 (19_Supplement): 4538.

https://doi.org/10.1158/1538-7445.AM2014-4538

Published: 01 October 2014

View articletitled, Abstract 4538: BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 311: Optimization of treatment schedule for the combination therapy of ATR inhibitor elimusertib and PARP inhibitor niraparib in preclinical tumor models

Abstract 2077: Activity of DHODH inhibitor BAY2402234 in subcutaneous and intracranial models of SCLC

Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation

Abstract 3927: Radium-223 α-particle radiation: Characterization of the in vitro effects on cancer cells in monotherapy and in combination with DNA repair inhibitors

Abstract 272: Synergistic activity of the ATR inhibitor BAY1895344 in combination with immune checkpoint inhibitors in preclinical tumor models

Abstract 321: Synergistic activity of the ATR inhibitor BAY 1895344 in combination with DNA damage inducing and DNA repair compromising therapies in preclinical tumor models

Abstract 849: Synergistic effect of MSLN-TTC in combination with DNA damage response inhibitors

Abstract 838: Synergistic in vivo activity of the ATR inhibitor BAY 1895344 in combination with the targeted alpha therapy radium-223 dichloride in a preclinical tumor model mimicking bone metastatic castration-resistant prostate cancer (mCRPC)

Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity

Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models

Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models

Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops

Abstract 2718: Synthesis and characterization of novel benzylpyrazole-based BUB1 kinase inhibitors with anti-tumor activity

Abstract 2725: Probing mitotic functions of BUB1 kinase using the small molecule inhibitors BAY-320 and BAY-524

Abstract DDT02-02: BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis

Abstract 2828: Rapid identification of potent and highly selective, oral PTEFb Inhibitor BAY 1143572 with first in class potential

Abstract 3098: The effects of a pan-cyclin dependent kinase (CDK) inhibitor and its combination with cisplatin in nasopharyngeal carcinoma (NPC)

Abstract 3090: Novel Mps1 kinase inhibitors with potent anti-tumor activity

Abstract 4540: SAC abrogation by MPS1 kinase inhibition: preclinical proof of concept of a novel approach to tumor treatment

Abstract 4538: BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only